TXN and neoplasm: To further evaluate therapeutic efficacy, tumor-bearing mice at a further advanced stage were immunized with either the Trx-8mer-flank E7-OVX313 antigen, or with the E7-lacking, Trx-8mer-OVX313 construct as a control, (Fig 8A).